Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot104310.32687/0869-866X-2022-30-s1-961-965Научная статьяEXPERIENCE IN ORGANIZING THE WORK OF THE CENTER FOR PERSONALIZED TREATMENT OF MALIGNANT NEOPLASMS (NETHERLANDS)AndreevD. A.andreevda@zdrav.mos.ruZavyalovA. A.-Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentBurnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency1511202230s196196517112022Copyright © 2022,2022Introduction. In the last decade, there has been a «breakthrough» development of scientific approaches to the assay of genomic and immune factors underlying anti-cancer treatment efficiency. The choice of antitumor therapy in practice is increasingly determined by molecular signatures, and not only by the specificity of organ tumor originated from (or by the histological properties of the tumor). An urgent and important scientific and practical task is to study the successful experience of organizing Centers for Personalized Cancer Treatment (CPCT).Aim: analysis of the 10-year experience of the Clinical Center for Personalized Cancer Treatment in the Netherlands.Materials and methods. Data were extracted from the internet databases using keywords: personalized cancer therapy / treatment, cancer, targeted therapy etc.Results. The Center's research project collects data on patients with metastatic cancer who are eligible for anticancer treatment as part of standard practice. The system accumulates various information about tumor DNA, mutations and abnormalities in DNA, treatment results (outcomes), as well as other important clinical characteristics, including individual tumor process. Registered parameters are stored in a digital database and are available for scientific research.Discussion and Conclusions. CPCT consider the possibilities for the more in-depth genomic analysis of patient DNA (including non-tumor DNA) in the future in order to improve the medical decision making regarding early diagnosis and personalized choice of anticancer therapies. Rapid progress will lead to the emergence of more advanced methods for re-evaluating biological samples accumulated in biobanks, that will facilitate the understanding the pillars of personalized anti-cancer treatment approaches as well as create an additional bases for the new drug development.organization of oncological caremalignant neoplasmsmolecular markersgenomic studiesindividualized antitumor therapyорганизация онкологической помощиперсонализациязлокачественные опухолимолекулярные маркерыгеномные исследованияиндивидуализированная противоопухолевая терапия1.Tsimberidou A. M., Fountzilas E., Nikanjam M., Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm // Cancer Treat. Rev. 2020. Vol. 86. P. 102019.2.Sleijfer S. Podcast (voormalig voorzitter bestuur stichting CPCT): Wat heeft DNA te maken met kanker? 2022. URL: https://lnkd.in/dG6wPxx (дата обращения 17.05.2022).3.MEDtalks, Voest E., Cuppen E., Sleijfer S. et al. 10 jaar Center for Personalized Cancer Treatment. 2022. URL: https://www.medtalks.nl/cpct10jaar (дата обращения 17.05.2022).4.Stichting CPCT. Jaarverslag 2020. URL: https://www.cpct.nl/wp-content/uploads/2021/04/Jaarverslag-2020-versie-definitief-met-verklaring.pdf (дата обращения 17.05.2022).5.Risk en Business, van Stigt Thans J. Europese vergelijking: Meer kanker in Nederland dan in andere EU-landen. 2020. URL: https://www.riskenbusiness.nl/nieuws/claims/europese-vergelijking-meer-kanker-in-nederland-dan-in-andere-eu-landen/(дата обращения 11.08.2022).6.Андреев Д. А. Анализ опыта оценки качества медицинской деятельности в онкологии на примере стран Западной Европы. 2020. URL: https://niioz.ru/news/zapis-i-itogi-vebinara-niiozmm-dzm-po-voprosam-kontrolya-kachestva-i-bezopasnosti-v-onkologicheskoy-/(дата обращения 11.08.2022).7.European Commission. Cancer burden statistics and trends across Europe. 2020. URL: https://ecis.jrc.ec.europa.eu/%0A (дата обращения 21.10.2020).8.Hartwig Medical Foundation. Onze visie op de toekomst van diagnostiek van patienten met kanker. 2022. URL: https://youtu.be/IMQb8B3aSPU (дата обращения 17.05.2022).9.Het Center for Personalized Cancer Treatment. Publicaties. URL: https://www.cpct.nl/onderzoekers/publicaties/(дата обращения 23.05.2022).10.CPCT. Drug Rediscovery Protocol DRUP studie. 2022. URL: https://www.cpct.nl/studie-info/(дата обращения 18.05.2022).11.Priestley P., Baber J., Lolkema M. P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours // Nature. 2019. Vol. 575, N 7781. P. 210-216.12.Pleguezuelos-Manzano C., Puschhof J., Rosendahl Huber A. et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli // Nature. 2020. Vol. 580, N 7802. P. 269-273. DOI: 10.1038/s41586-020-2080-813.Tsunematsu Y., Hosomi K., Kunisawa J. et al. Mother-to-infant transmission of the carcinogenic colibactin-producing bacteria // BMC Microbiol. 2021. Vol. 21, N 1. P. 235.14.Hoshino I., Yokota H. Radiogenomics of gastroenterological cancer: The dawn of personalized medicine with artificial intelligence-based image analysis // Ann. Gastroenterol. Surg. 2021. Vol. 5, N 4. P. 427-435.15.Рожкова Н. И., Боженко В. К., Бурдина И. И. и др. Радиогеномика рака молочной железы - новый вектор междисциплинарной интеграции лучевых и молекулярно-биологических технологий (обзор литературы) // Медицинский алфавит. 2020. № 20. С. 21-29.16.Davis I., Morgans A. IRONMAN: International Registry for Men with Advanced Prostate Cancer. URL: https://www.apccc.org/fileadmin/files/2019/apccc2019/slides/IRONMAN.pdf (дата обращения 22.05.2022).17.van Riet J., Saha C., Strepis N. et al. CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue // Commun. Biol. 2022. Vol. 5, N 1. P. 338.18.Lopez-Guerrero J. A., Mendiola M., Perez-Fidalgo J. A. et al. Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network // Cancers (Basel). 2022. Vol. 14, N 8. P. 1965.